Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Reviews in Endocrine and Metabolic Disorders
Published in: Reviews in Endocrine and Metabolic Disorders 5/2022

13-06-2022 | Insulins

Posttranslational modifications in diabetes: Mechanisms and functions

Authors: Ang Hu, Haohong Zou, Bin Chen, Jianing Zhong

Published in: Reviews in Endocrine and Metabolic Disorders | Issue 5/2022

Login to get access

Abstract

As one of the most widespread chronic diseases, diabetes and its accompanying complications affect approximately one tenth of individuals worldwide and represent a growing cause of morbidity and mortality. Accumulating evidence has proven that the process of diabetes is complex and interactive, involving various cellular responses and signaling cascades by posttranslational modifications (PTMs). Therefore, understanding the mechanisms and functions of PTMs in regulatory networks has fundamental importance for understanding the prediction, onset, diagnosis, progression, and treatment of diabetes. In this review, we offer a holistic summary and illustration of the crosstalk between PTMs and diabetes, including both types 1 and 2. Meanwhile, we discuss the potential use of PTMs in diabetes treatment and provide a prospective direction for deeply understanding the metabolic diseases.
Appendix
Available only for authorised users
Literature
1.
Standl E, Khunti K, Hansen TB, Schnell O. The global epidemics of diabetes in the 21st century: Current situation and perspectives. Eur J Prev Cardiol. 2019;26(2_suppl):7–14.
2.
Koye DN, Magliano DJ, Nelson RG, Pavkov ME. The Global Epidemiology of Diabetes and Kidney Disease. Adv Chronic Kidney Dis. 2018;25(2):121–32.PubMedCrossRef
3.
Bauer W, Gyenesei A, Krętowski A. The Multifactorial Progression from the Islet Autoimmunity to Type 1 Diabetes in Children. Int J Mol Sci. 2021;22(14).
4.
5.
6.
Ismail L, Materwala H, Al Kaabi J. Association of risk factors with type 2 diabetes: A systematic review. Comput Struct Biotechnol J. 2021;19:1759–85.PubMedPubMedCentralCrossRef
7.
Tinajero MG, Malik VS. An Update on the Epidemiology of Type 2 Diabetes: A Global Perspective. Endocrinol Metab Clin North Am. 2021;50(3):337–55.PubMedCrossRef
8.
Weisman A, Fazli GS, Johns A, Booth GL. Evolving Trends in the Epidemiology, Risk Factors, and Prevention of Type 2 Diabetes: A Review. Can J Cardiol. 2018;34(5):552–64.PubMedCrossRef
9.
Tarazona OA, Pourquié O. Exploring the Influence of Cell Metabolism on Cell Fate through Protein Post-translational Modifications. Dev Cell. 2020;54(2):282–92.PubMedPubMedCentralCrossRef
10.
11.
James EA, Pietropaolo M, Mamula MJ. Immune Recognition of β-Cells: Neoepitopes as Key Players in the Loss of Tolerance. Diabetes. 2018;67(6):1035–42.PubMedPubMedCentralCrossRef
12.
Callebaut A, Derua R, Vig S, Delong T, Mathieu C, Overbergh L. Identification of Deamidated Peptides in Cytokine-Exposed MIN6 Cells through LC-MS/MS Using a Shortened Digestion Time and Inspection of MS2 Spectra. J Proteome Res. 2021;20(2):1405–14.PubMedCrossRef
13.
Marré ML, Profozich JL, Coneybeer JT, Geng X, Bertera S, Ford MJ, et al. Inherent ER stress in pancreatic islet β cells causes self-recognition by autoreactive T cells in type 1 diabetes. J Autoimmun. 2016;72:33–46.PubMedPubMedCentralCrossRef
14.
Marre ML, McGinty JW, Chow IT, DeNicola ME, Beck NW, Kent SC, et al. Modifying Enzymes Are Elicited by ER Stress, Generating Epitopes That Are Selectively Recognized by CD4(+) T Cells in Patients With Type 1 Diabetes. Diabetes. 2018;67(7):1356–68.PubMedPubMedCentralCrossRef
15.
Yang ML, Doyle HA, Clarke SG, Herold KC, Mamula MJ. Oxidative Modifications in Tissue Pathology and Autoimmune Disease. Antioxid Redox Signal. 2018;29(14):1415–31.PubMedPubMedCentralCrossRef
16.
17.
Pérez-Torres I, Soto ME, Castrejón-Tellez V, Rubio-Ruiz ME, Manzano Pech L, Guarner-Lans V. Oxidative, Reductive, and Nitrosative Stress Effects on Epigenetics and on Posttranslational Modification of Enzymes in Cardiometabolic Diseases. Oxid Med Cell Longev. 2020;2020:8819719.PubMedPubMedCentralCrossRef
18.
McLaughlin RJ, de Haan A, Zaldumbide A, de Koning EJ, de Ru AH, van Veelen PA, et al. Human islets and dendritic cells generate post-translationally modified islet autoantigens. Clin Exp Immunol. 2016;185(2):133–40.PubMedPubMedCentralCrossRef
19.
Buitinga M, Callebaut A, Marques Câmara Sodré F, Crèvecoeur I, Blahnik-Fagan G, Yang ML, et al. Inflammation-Induced Citrullinated Glucose-Regulated Protein 78 Elicits Immune Responses in Human Type 1 Diabetes. Diabetes. 2018;67(11):2337–48.
20.
Schuit FC, In’t Veld PA, Pipeleers DG. Glucose stimulates proinsulin biosynthesis by a dose-dependent recruitment of pancreatic beta cells. Proc Natl Acad Sci U S A. 1988;85(11):3865–9.PubMedPubMedCentralCrossRef
21.
22.
23.
24.
Marroqui L, Dos Santos RS, Coomans de Brachène A, Marselli L, Marchetti P, Eizirik DL. Interferon-α mediates human beta cell HLA class I overexpression, endoplasmic reticulum stress and apoptosis, three hallmarks of early human type 1 diabetes. Diabetologia. 2017;60(4):656–67.
25.
Ramos-Rodríguez M, Raurell-Vila H, Colli ML, Alvelos MI, Subirana-Granés M, Juan-Mateu J, et al. The impact of proinflammatory cytokines on the β-cell regulatory landscape provides insights into the genetics of type 1 diabetes. Nat Genet. 2019;51(11):1588–95.PubMedPubMedCentralCrossRef
26.
Yeung WC, Rawlinson WD, Craig ME. Enterovirus infection and type 1 diabetes mellitus: systematic review and meta-analysis of observational molecular studies. BMJ. 2011;342: d35.PubMedPubMedCentralCrossRef
27.
Lönnrot M, Salminen K, Knip M, Savola K, Kulmala P, Leinikki P, et al. Enterovirus RNA in serum is a risk factor for beta-cell autoimmunity and clinical type 1 diabetes: a prospective study Childhood Diabetes in Finland (DiMe) Study Group. J Med Virol. 2000;61(2):214–20.PubMedCrossRef
28.
Akhbari P, Richardson SJ, Morgan NG. Type 1 Diabetes: Interferons and the Aftermath of Pancreatic Beta-Cell Enteroviral Infection. Microorganisms. 2020;8(9).
29.
Colli ML, Paula FM, Marselli L, Marchetti P, Roivainen M, Eizirik DL, et al. Coxsackievirus B Tailors the Unfolded Protein Response to Favour Viral Amplification in Pancreatic β Cells. J Innate Immun. 2019;11(4):375–90.PubMedPubMedCentralCrossRef
30.
Santin I, Eizirik DL. Candidate genes for type 1 diabetes modulate pancreatic islet inflammation and β-cell apoptosis. Diabetes Obes Metab. 2013;15(Suppl 3):71–81.PubMedCrossRef
31.
Colli ML, Moore F, Gurzov EN, Ortis F, Eizirik DL. MDA5 and PTPN2, two candidate genes for type 1 diabetes, modify pancreatic beta-cell responses to the viral by-product double-stranded RNA. Hum Mol Genet. 2010;19(1):135–46.PubMedCrossRef
32.
Heikkila RE, Winston B, Cohen G. Alloxan-induced diabetes-evidence for hydroxyl radical as a cytotoxic intermediate. Biochem Pharmacol. 1976;25(9):1085–92.PubMedCrossRef
33.
Takasu N, Komiya I, Asawa T, Nagasawa Y, Yamada T. Streptozocin- and alloxan-induced H2O2 generation and DNA fragmentation in pancreatic islets H2O2 as mediator for DNA fragmentation. Diabetes. 1991;40(9):1141–5.PubMedCrossRef
34.
Bedoya FJ, Solano F, Lucas M. N-monomethyl-arginine and nicotinamide prevent streptozotocin-induced double strand DNA break formation in pancreatic rat islets. Experientia. 1996;52(4):344–7.PubMedCrossRef
35.
Sandler S, Swenne I. Streptozotocin, but not alloxan, induces DNA repair synthesis in mouse pancreatic islets in vitro. Diabetologia. 1983;25(5):444–7.PubMedCrossRef
36.
Campbell-Thompson M, Wasserfall C, Montgomery EL, Atkinson MA, Kaddis JS. Pancreas organ weight in individuals with disease-associated autoantibodies at risk for type 1 diabetes. JAMA. 2012;308(22):2337–9.PubMedCrossRef
37.
Yaribeygi H, Sathyapalan T, Atkin SL, Sahebkar A. Molecular Mechanisms Linking Oxidative Stress and Diabetes Mellitus. Oxid Med Cell Longev. 2020;2020:8609213.PubMedPubMedCentralCrossRef
38.
Drews G, Krippeit-Drews P, Düfer M. Oxidative stress and beta-cell dysfunction. Pflugers Arch. 2010;460(4):703–18.PubMedCrossRef
39.
Piganelli JD, Mamula MJ, James EA. The Role of β Cell Stress and Neo-Epitopes in the Immunopathology of Type 1 Diabetes. Front Endocrinol (Lausanne). 2020;11: 624590.CrossRef
40.
Doyle HA, Mamula MJ. Autoantigenesis: the evolution of protein modifications in autoimmune disease. Curr Opin Immunol. 2012;24(1):112–8.PubMedCrossRef
41.
42.
43.
Mariño E, Batten M, Groom J, Walters S, Liuwantara D, Mackay F, et al. Marginal-zone B-cells of nonobese diabetic mice expand with diabetes onset, invade the pancreatic lymph nodes, and present autoantigen to diabetogenic T-cells. Diabetes. 2008;57(2):395–404.PubMedCrossRef
44.
Mariño E, Tan B, Binge L, Mackay CR, Grey ST. B-cell cross-presentation of autologous antigen precipitates diabetes. Diabetes. 2012;61(11):2893–905.PubMedPubMedCentralCrossRef
45.
Martin S, Wolf-Eichbaum D, Duinkerken G, Scherbaum WA, Kolb H, Noordzij JG, et al. Development of type 1 diabetes despite severe hereditary B-cell deficiency. N Engl J Med. 2001;345(14):1036–40.PubMedCrossRef
46.
47.
Gonzalez-Duque S, Azoury ME, Colli ML, Afonso G, Turatsinze JV, Nigi L, et al. Conventional and Neo-antigenic Peptides Presented by β Cells Are Targeted by Circulating Naïve CD8+ T Cells in Type 1 Diabetic and Healthy Donors. Cell Metab. 2018;28(6):946-960.e946.PubMedCrossRef
48.
Culina S, Lalanne AI, Afonso G, Cerosaletti K, Pinto S, Sebastiani G, et al. Islet-reactive CD8(+) T cell frequencies in the pancreas, but not in blood, distinguish type 1 diabetic patients from healthy donors. Sci Immunol. 2018;3(20).
49.
Monti P, Heninger AK, Bonifacio E. Differentiation, expansion, and homeostasis of autoreactive T cells in type 1 diabetes mellitus. Curr Diab Rep. 2009;9(2):113–8.PubMedCrossRef
50.
Oling V, Reijonen H, Simell O, Knip M, Ilonen J. Autoantigen-specific memory CD4+ T cells are prevalent early in progression to Type 1 diabetes. Cell Immunol. 2012;273(2):133–9.PubMedCrossRef
51.
Chujo D, Foucat E, Nguyen TS, Chaussabel D, Banchereau J, Ueno H. ZnT8-Specific CD4+ T cells display distinct cytokine expression profiles between type 1 diabetes patients and healthy adults. PLoS ONE. 2013;8(2): e55595.PubMedPubMedCentralCrossRef
52.
Arif S, Tree TI, Astill TP, Tremble JM, Bishop AJ, Dayan CM, et al. Autoreactive T cell responses show proinflammatory polarization in diabetes but a regulatory phenotype in health. J Clin Invest. 2004;113(3):451–63.PubMedPubMedCentralCrossRef
53.
van Lummel M, Duinkerken G, van Veelen PA, de Ru A, Cordfunke R, Zaldumbide A, et al. Posttranslational modification of HLA-DQ binding islet autoantigens in type 1 diabetes. Diabetes. 2014;63(1):237–47.PubMedCrossRef
54.
55.
Hill JA, Southwood S, Sette A, Jevnikar AM, Bell DA, Cairns E. Cutting edge: the conversion of arginine to citrulline allows for a high-affinity peptide interaction with the rheumatoid arthritis-associated HLA-DRB1*0401 MHC class II molecule. J Immunol. 2003;171(2):538–41.PubMedCrossRef
56.
James EA, Moustakas AK, Bui J, Papadopoulos GK, Bondinas G, Buckner JH, et al. HLA-DR1001 presents “altered-self” peptides derived from joint-associated proteins by accepting citrulline in three of its binding pockets. Arthritis Rheum. 2010;62(10):2909–18.PubMedPubMedCentralCrossRef
57.
58.
Wang Y, Sosinowski T, Novikov A, Crawford F, Neau DB, Yang J, et al. C-terminal modification of the insulin B:11–23 peptide creates superagonists in mouse and human type 1 diabetes. Proc Natl Acad Sci U S A. 2018;115(1):162–7.PubMedCrossRef
59.
McGinty JW, Chow IT, Greenbaum C, Odegard J, Kwok WW, James EA. Recognition of posttranslationally modified GAD65 epitopes in subjects with type 1 diabetes. Diabetes. 2014;63(9):3033–40.PubMedPubMedCentralCrossRef
60.
Gottlieb PA, Delong T, Baker RL, Fitzgerald-Miller L, Wagner R, Cook G, et al. Chromogranin A is a T cell antigen in human type 1 diabetes. J Autoimmun. 2014;50:38–41.PubMedCrossRef
61.
Delong T, Baker RL, He J, Barbour G, Bradley B, Haskins K. Diabetogenic T-cell clones recognize an altered peptide of chromogranin A. Diabetes. 2012;61(12):3239–46.PubMedPubMedCentralCrossRef
62.
Donnelly C, Williams A. Investigating the potential impact of post translational modification of auto-antigens by tissue transglutaminase on humoral islet autoimmunity in type 1 diabetes. Metabol Open. 2020;8: 100062.PubMedPubMedCentralCrossRef
63.
Sidney J, Vela JL, Friedrich D, Kolla R, von Herrath M, Wesley JD, et al. Low HLA binding of diabetes-associated CD8+ T-cell epitopes is increased by post translational modifications. BMC Immunol. 2018;19(1):12.PubMedPubMedCentralCrossRef
64.
Babon JA, DeNicola ME, Blodgett DM, Crèvecoeur I, Buttrick TS, Maehr R, et al. Analysis of self-antigen specificity of islet-infiltrating T cells from human donors with type 1 diabetes. Nat Med. 2016;22(12):1482–7.PubMedPubMedCentralCrossRef
65.
Rondas D, Crèvecoeur I, D’Hertog W, Ferreira GB, Staes A, Garg AD, et al. Citrullinated glucose-regulated protein 78 is an autoantigen in type 1 diabetes. Diabetes. 2015;64(2):573–86.PubMedCrossRef
66.
Sun B, Chang HH, Salinger A, Tomita B, Bawadekar M, Holmes CL, et al. Reciprocal regulation of Th2 and Th17 cells by PAD2-mediated citrullination. JCI Insight. 2019;4(22).
67.
Mannering SI, Harrison LC, Williamson NA, Morris JS, Thearle DJ, Jensen KP, et al. The insulin A-chain epitope recognized by human T cells is posttranslationally modified. J Exp Med. 2005;202(9):1191–7.PubMedPubMedCentralCrossRef
68.
Strollo R, Vinci C, Napoli N, Fioriti E, Maddaloni E, Åkerman L, et al. Antibodies to oxidized insulin improve prediction of type 1 diabetes in children with positive standard islet autoantibodies. Diabetes Metab Res Rev. 2019;35(4): e3132.PubMedCrossRef
69.
Arif Z, Neelofar K, Arfat MY, Zaman A, Tarannum A, Parveen I, et al. Hyperglycemia induced reactive species trigger structural changes in human serum albumin of type 1 diabetic subjects. Int J Biol Macromol. 2018;107(Pt B):2141–9.PubMedCrossRef
70.
71.
Mziaut H, Trajkovski M, Kersting S, Ehninger A, Altkrüger A, Lemaitre RP, et al. Synergy of glucose and growth hormone signalling in islet cells through ICA512 and STAT5. Nat Cell Biol. 2006;8(5):435–45.PubMedCrossRef
72.
Kishi A, Nakamura T, Nishio Y, Maegawa H, Kashiwagi A. Sumoylation of Pdx1 is associated with its nuclear localization and insulin gene activation. Am J Physiol Endocrinol Metab. 2003;284(4):E830-840.PubMedCrossRef
73.
Fajans SS, Bell GI, Polonsky KS. Molecular mechanisms and clinical pathophysiology of maturity-onset diabetes of the young. N Engl J Med. 2001;345(13):971–80.PubMedCrossRef
74.
Kaci A, Keindl M, Solheim MH, Njølstad PR, Bjørkhaug L, Aukrust I. The E3 SUMO ligase PIASγ is a novel interaction partner regulating the activity of diabetes associated hepatocyte nuclear factor-1α. Sci Rep. 2018;8(1):12780.PubMedPubMedCentralCrossRef
75.
He X, Lai Q, Chen C, Li N, Sun F, Huang W, et al. Both conditional ablation and overexpression of E2 SUMO-conjugating enzyme (UBC9) in mouse pancreatic beta cells result in impaired beta cell function. Diabetologia. 2018;61(4):881–95.PubMedCrossRef
76.
Hajmrle C, Ferdaoussi M, Plummer G, Spigelman AF, Lai K, Manning Fox JE, et al. SUMOylation protects against IL-1β-induced apoptosis in INS-1 832/13 cells and human islets. Am J Physiol Endocrinol Metab. 2014;307(8):E664-673.PubMedPubMedCentralCrossRef
77.
Shao L, Zhou HJ, Zhang H, Qin L, Hwa J, Yun Z, et al. SENP1-mediated NEMO deSUMOylation in adipocytes limits inflammatory responses and type-1 diabetes progression. Nat Commun. 2015;6:8917.PubMedCrossRef
78.
Hsu CY, Yeh LT, Fu SH, Chien MW, Liu YW, Miaw SC, et al. SUMO-defective c-Maf preferentially transactivates Il21 to exacerbate autoimmune diabetes. J Clin Invest. 2018;128(9):3779–93.PubMedPubMedCentralCrossRef
79.
Wang F, Sun F, Luo J, Yue T, Chen L, Zhou H, et al. Loss of ubiquitin-conjugating enzyme E2 (Ubc9) in macrophages exacerbates multiple low-dose streptozotocin-induced diabetes by attenuating M2 macrophage polarization. Cell Death Dis. 2019;10(12):892.PubMedPubMedCentralCrossRef
80.
Aribi M. Candidate genes implicated in type 1 diabetes susceptibility. Curr Diabetes Rev. 2008;4(2):110–21.PubMedCrossRef
81.
Strollo R, Vinci C, Arshad MH, Perrett D, Tiberti C, Chiarelli F, et al. Antibodies to post-translationally modified insulin in type 1 diabetes. Diabetologia. 2015;58(12):2851–60.PubMedCrossRef
82.
Nuti F, Gallo A, Real-Fernandez F, Crulli M, Rentier C, Piarulli F, et al. Antibodies to post-translationally modified mitochondrial peptide PDC-E2(167–184) in type 1 diabetes. Arch Biochem Biophys. 2018;659:66–74.PubMedCrossRef
83.
Ramakrishnan P, Clark PM, Mason DE, Peters EC, Hsieh-Wilson LC, Baltimore D. Activation of the transcriptional function of the NF-κB protein c-Rel by O-GlcNAc glycosylation. Sci Signal. 2013;6(290):ra75.
84.
de Jesus TJ, Tomalka JA, Centore JT, Staback Rodriguez FD, Agarwal RA, Liu AR, et al. Negative regulation of FOXP3 expression by c-Rel O-GlcNAcylation. Glycobiology. 2021;31(7):812–26.PubMedPubMedCentralCrossRef
85.
Draznin B, Aroda VR, Bakris G, Benson G, Brown FM, Freeman R, et al. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022;45(Supplement_1):S125-43.
86.
Sodré FMC, Bissenova S, Bruggeman Y, Tilvawala R, Cook DP, Berthault C, et al. Peptidylarginine Deiminase Inhibition Prevents Diabetes Development in NOD Mice. Diabetes. 2021;70(2):516–28.PubMedCrossRef
87.
Kawalkowska J, Quirke AM, Ghari F, Davis S, Subramanian V, Thompson PR, et al. Abrogation of collagen-induced arthritis by a peptidyl arginine deiminase inhibitor is associated with modulation of T cell-mediated immune responses. Sci Rep. 2016;6:26430.PubMedPubMedCentralCrossRef
88.
Knight JS, Subramanian V, O’Dell AA, Yalavarthi S, Zhao W, Smith CK, et al. Peptidylarginine deiminase inhibition disrupts NET formation and protects against kidney, skin and vascular disease in lupus-prone MRL/lpr mice. Ann Rheum Dis. 2015;74(12):2199–206.PubMedCrossRef
89.
Kawaguchi H, Matsumoto I, Osada A, Kurata I, Ebe H, Tanaka Y, et al. Peptidyl arginine deiminase inhibition suppresses arthritis via decreased protein citrullination in joints and serum with the downregulation of interleukin-6. Mod Rheumatol. 2019;29(6):964–9.PubMedCrossRef
90.
Roep BO, Thomaidou S, van Tienhoven R, Zaldumbide A. Type 1 diabetes mellitus as a disease of the β-cell (do not blame the immune system?). Nat Rev Endocrinol. 2021;17(3):150–61.PubMedCrossRef
91.
92.
Vercoutter-Edouart AS, El Yazidi-Belkoura I, Guinez C, Baldini S, Leturcq M, Mortuaire M, et al. Detection and identification of O-GlcNAcylated proteins by proteomic approaches. Proteomics. 2015;15(5–6):1039–50.PubMedCrossRef
93.
Marshall S, Bacote V, Traxinger RR. Discovery of a metabolic pathway mediating glucose-induced desensitization of the glucose transport system. Role of hexosamine biosynthesis in the induction of insulin resistance. J Biol Chem. 1991;266(8):4706–12.PubMedCrossRef
94.
McClain DA, Lubas WA, Cooksey RC, Hazel M, Parker GJ, Love DC, et al. Altered glycan-dependent signaling induces insulin resistance and hyperleptinemia. Proc Natl Acad Sci U S A. 2002;99(16):10695–9.PubMedPubMedCentralCrossRef
95.
Vosseller K, Wells L, Lane MD, Hart GW. Elevated nucleocytoplasmic glycosylation by O-GlcNAc results in insulin resistance associated with defects in Akt activation in 3T3-L1 adipocytes. Proc Natl Acad Sci U S A. 2002;99(8):5313–8.PubMedPubMedCentralCrossRef
96.
Sermikli BP, Aydogdu G, Yilmaz E. Role of the O-GlcNAc modification on insulin resistance and endoplasmic reticulum stress in 3T3-L1 cells. Mol Biol Rep. 2020;47(8):5927–42.PubMedCrossRef
97.
Teo CF, Wollaston-Hayden EE, Wells L. Hexosamine flux, the O-GlcNAc modification, and the development of insulin resistance in adipocytes. Mol Cell Endocrinol. 2010;318(1–2):44–53.PubMedCrossRef
98.
Alejandro EU, Bozadjieva N, Kumusoglu D, Abdulhamid S, Levine H, Haataja L, et al. Disruption of O-linked N-Acetylglucosamine Signaling Induces ER Stress and β Cell Failure. Cell Rep. 2015;13(11):2527–38.PubMedPubMedCentralCrossRef
99.
Andrali SS, Qian Q, Ozcan S. Glucose mediates the translocation of NeuroD1 by O-linked glycosylation. J Biol Chem. 2007;282(21):15589–96.PubMedCrossRef
100.
Kebede M, Ferdaoussi M, Mancini A, Alquier T, Kulkarni RN, Walker MD, et al. Glucose activates free fatty acid receptor 1 gene transcription via phosphatidylinositol-3-kinase-dependent O-GlcNAcylation of pancreas-duodenum homeobox-1. Proc Natl Acad Sci U S A. 2012;109(7):2376–81.PubMedPubMedCentralCrossRef
101.
Kang ES, Han D, Park J, Kwak TK, Oh MA, Lee SA, et al. O-GlcNAc modulation at Akt1 Ser473 correlates with apoptosis of murine pancreatic beta cells. Exp Cell Res. 2008;314(11–12):2238–48.PubMedCrossRef
102.
103.
Liu K, Paterson AJ, Chin E, Kudlow JE. Glucose stimulates protein modification by O-linked GlcNAc in pancreatic beta cells: linkage of O-linked GlcNAc to beta cell death. Proc Natl Acad Sci U S A. 2000;97(6):2820–5.PubMedPubMedCentralCrossRef
104.
Federici M, Hribal M, Perego L, Ranalli M, Caradonna Z, Perego C, et al. High glucose causes apoptosis in cultured human pancreatic islets of Langerhans: a potential role for regulation of specific Bcl family genes toward an apoptotic cell death program. Diabetes. 2001;50(6):1290–301.PubMedCrossRef
105.
Very N, Vercoutter-Edouart AS, Lefebvre T, Hardivillé S, El Yazidi-Belkoura I. Cross-Dysregulation of O-GlcNAcylation and PI3K/AKT/mTOR Axis in Human Chronic Diseases. Front Endocrinol (Lausanne). 2018;9:602.CrossRef
106.
Whelan SA, Dias WB, Thiruneelakantapillai L, Lane MD, Hart GW. Regulation of insulin receptor substrate 1 (IRS-1)/AKT kinase-mediated insulin signaling by O-Linked beta-N-acetylglucosamine in 3T3-L1 adipocytes. J Biol Chem. 2010;285(8):5204–11.PubMedCrossRef
107.
108.
Yang X, Ongusaha PP, Miles PD, Havstad JC, Zhang F, So WV, et al. Phosphoinositide signalling links O-GlcNAc transferase to insulin resistance. Nature. 2008;451(7181):964–9.PubMedCrossRef
109.
McClung JP, Roneker CA, Mu W, Lisk DJ, Langlais P, Liu F, et al. Development of insulin resistance and obesity in mice overexpressing cellular glutathione peroxidase. Proc Natl Acad Sci U S A. 2004;101(24):8852–7.PubMedPubMedCentralCrossRef
110.
Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414(6865):813–20.PubMedCrossRef
111.
Lim JM, Wollaston-Hayden EE, Teo CF, Hausman D, Wells L. Quantitative secretome and glycome of primary human adipocytes during insulin resistance. Clin Proteomics. 2014;11(1):20.PubMedPubMedCentralCrossRef
112.
113.
Sharma NS, Saluja AK, Banerjee S. “Nutrient-sensing” and self-renewal: O-GlcNAc in a new role. J Bioenerg Biomembr. 2018;50(3):205–11.PubMedCrossRef
114.
Baldini SF, Steenackers A, Olivier-Van Stichelen S, Mir AM, Mortuaire M, Lefebvre T, et al. Glucokinase expression is regulated by glucose through O-GlcNAc glycosylation. Biochem Biophys Res Commun. 2016;478(2):942–8.PubMedCrossRef
115.
Koch LG, Britton SL, Wisløff U. A rat model system to study complex disease risks, fitness, aging, and longevity. Trends Cardiovasc Med. 2012;22(2):29–34.PubMedPubMedCentralCrossRef
116.
Cieniewski-Bernard C, Lambert M, Dupont E, Montel V, Stevens L, Bastide B. O-GlcNAcylation, contractile protein modifications and calcium affinity in skeletal muscle. Front Physiol. 2014;5:421.PubMedPubMedCentralCrossRef
117.
Macauley MS, Shan X, Yuzwa SA, Gloster TM, Vocadlo DJ. Elevation of Global O-GlcNAc in rodents using a selective O-GlcNAcase inhibitor does not cause insulin resistance or perturb glucohomeostasis. Chem Biol. 2010;17(9):949–58.PubMedPubMedCentralCrossRef
118.
Macauley MS, Bubb AK, Martinez-Fleites C, Davies GJ, Vocadlo DJ. Elevation of global O-GlcNAc levels in 3T3-L1 adipocytes by selective inhibition of O-GlcNAcase does not induce insulin resistance. J Biol Chem. 2008;283(50):34687–95.PubMedPubMedCentralCrossRef
119.
Macauley MS, He Y, Gloster TM, Stubbs KA, Davies GJ, Vocadlo DJ. Inhibition of O-GlcNAcase using a potent and cell-permeable inhibitor does not induce insulin resistance in 3T3-L1 adipocytes. Chem Biol. 2010;17(9):937–48.PubMedPubMedCentralCrossRef
120.
Yang YR, Jang HJ, Choi SS, Lee YH, Lee GH, Seo YK, et al. Obesity resistance and increased energy expenditure by white adipose tissue browning in Oga(+/-) mice. Diabetologia. 2015;58(12):2867–76.PubMedCrossRef
121.
Ida S, Morino K, Sekine O, Ohashi N, Kume S, Chano T, et al. Diverse metabolic effects of O-GlcNAcylation in the pancreas but limited effects in insulin-sensitive organs in mice. Diabetologia. 2017;60(9):1761–9.PubMedCrossRef
122.
Dentin R, Hedrick S, Xie J, Yates J 3rd, Montminy M. Hepatic glucose sensing via the CREB coactivator CRTC2. Science. 2008;319(5868):1402–5.PubMedCrossRef
123.
Robinson KA, Ball LE, Buse MG. Reduction of O-GlcNAc protein modification does not prevent insulin resistance in 3T3-L1 adipocytes. Am J Physiol Endocrinol Metab. 2007;292(3):E884-890.PubMedCrossRef
124.
Hwang JS, Park JW, Nam MS, Cho H, Han IO. Glucosamine enhances body weight gain and reduces insulin response in mice fed chow diet but mitigates obesity, insulin resistance and impaired glucose tolerance in mice high-fat diet. Metabolism. 2015;64(3):368–79.PubMedCrossRef
125.
Rossetti L, Hawkins M, Chen W, Gindi J, Barzilai N. In vivo glucosamine infusion induces insulin resistance in normoglycemic but not in hyperglycemic conscious rats. J Clin Invest. 1995;96(1):132–40.PubMedPubMedCentralCrossRef
126.
Wells L, Vosseller K, Hart GW. Glycosylation of nucleocytoplasmic proteins: signal transduction and O-GlcNAc. Science. 2001;291(5512):2376–8.PubMedCrossRef
127.
Wang Z, Gucek M, Hart GW. Cross-talk between GlcNAcylation and phosphorylation: site-specific phosphorylation dynamics in response to globally elevated O-GlcNAc. Proc Natl Acad Sci U S A. 2008;105(37):13793–8.PubMedPubMedCentralCrossRef
128.
Hart GW, Housley MP, Slawson C. Cycling of O-linked beta-N-acetylglucosamine on nucleocytoplasmic proteins. Nature. 2007;446(7139):1017–22.PubMedCrossRef
129.
130.
Stafeev IS, Sklyanik IA, Yah’yaev KA, Shestakova EA, Yurasov AV, Karmadonov AV, et al. Low AS160 and high SGK basal phosphorylation associates with impaired incretin profile and type 2 diabetes in adipose tissue of obese patients. Diabetes Res Clin Pract. 2019;158: 107928.PubMedCrossRef
131.
Li X, Molina H, Huang H, Zhang YY, Liu M, Qian SW, et al. O-linked N-acetylglucosamine modification on CCAAT enhancer-binding protein beta: role during adipocyte differentiation. J Biol Chem. 2009;284(29):19248–54.PubMedPubMedCentralCrossRef
132.
Lin Y, Liu J, Chen J, Yao C, Yang Y, Wang J, et al. FADD Phosphorylation Modulates Blood Glucose Levels by Decreasing the Expression of Insulin-Degrading Enzyme. Mol Cells. 2020;43(4):373–83.PubMedPubMedCentral
133.
Chen L, Sun X, Xiao H, Xu F, Yang Y, Lin Z, et al. PAQR3 regulates phosphorylation of FoxO1 in insulin-resistant HepG2 cells via NF-κB signaling pathway. Exp Cell Res. 2019;381(2):301–10.PubMedCrossRef
134.
Rada P, Mosquera A, Muntané J, Ferrandiz F, Rodriguez-Mañas L, de Pablo F, et al. Differential effects of metformin glycinate and hydrochloride in glucose production, AMPK phosphorylation and insulin sensitivity in hepatocytes from non-diabetic and diabetic mice. Food Chem Toxicol. 2019;123:470–80.PubMedCrossRef
135.
Cochrane VA, Wu Y, Yang Z, ElSheikh A, Dunford J, Kievit P, et al. Leptin modulates pancreatic β-cell membrane potential through Src kinase-mediated phosphorylation of NMDA receptors. J Biol Chem. 2020;295(50):17281–97.PubMedPubMedCentralCrossRef
136.
Kim JS, Kim WK, Oh KJ, Lee EW, Han BS, Lee SC, et al. Protein Tyrosine Phosphatase, Receptor Type B (PTPRB) Inhibits Brown Adipocyte Differentiation through Regulation of VEGFR2 Phosphorylation. J Microbiol Biotechnol. 2019;29(4):645–50.PubMedCrossRef
137.
138.
Rajan S, Torres J, Thompson MS, Philipson LH. SUMO downregulates GLP-1-stimulated cAMP generation and insulin secretion. Am J Physiol Endocrinol Metab. 2012;302(6):E714-723.PubMedPubMedCentralCrossRef
139.
Dai XQ, Plummer G, Casimir M, Kang Y, Hajmrle C, Gaisano HY, et al. SUMOylation regulates insulin exocytosis downstream of secretory granule docking in rodents and humans. Diabetes. 2011;60(3):838–47.PubMedPubMedCentralCrossRef
140.
Fu J, Githaka JM, Dai X, Plummer G, Suzuki K, Spigelman AF, et al. A glucose-dependent spatial patterning of exocytosis in human β-cells is disrupted in type 2 diabetes. JCI Insight. 2019;5(12).
141.
Yuan W, Ma C, Zhou Y, Wang M, Zeng G, Huang Q. Negative regulation of eNOS-NO signaling by over-SUMOylation of PPARγ contributes to insulin resistance and dysfunction of vascular endothelium in rats. Vascul Pharmacol. 2019;122–123: 106597.PubMedCrossRef
142.
Lan D, Shen X, Yuan W, Zhou Y, Huang Q. Sumoylation of PPARγ contributes to vascular endothelium insulin resistance through stabilizing the PPARγ-NcoR complex. J Cell Physiol. 2019;234(11):19663–74.PubMedCrossRef
143.
Li N, Zhang S, Xiong F, Eizirik DL, Wang CY. SUMOylation, a multifaceted regulatory mechanism in the pancreatic beta cells. Semin Cell Dev Biol. 2020;103:51–8.PubMedCrossRef
144.
Hu X, Zhang Q, Zheng J, Kong W, Zhang HH, Zeng TS, et al. Alteration of FXR phosphorylation and sumoylation in liver in the development of adult catch-up growth. Exp Biol Med (Maywood). 2017;242(3):297–304.CrossRef
145.
146.
Benhamed F, Filhoulaud G, Caron S, Lefebvre P, Staels B, Postic C. O-GlcNAcylation Links ChREBP and FXR to Glucose-Sensing. Front Endocrinol (Lausanne). 2014;5:230.
147.
Balasubramaniyan N, Luo Y, Sun AQ, Suchy FJ. SUMOylation of the farnesoid X receptor (FXR) regulates the expression of FXR target genes. J Biol Chem. 2013;288(19):13850–62.PubMedPubMedCentralCrossRef
148.
149.
Bricambert J, Miranda J, Benhamed F, Girard J, Postic C, Dentin R. Salt-inducible kinase 2 links transcriptional coactivator p300 phosphorylation to the prevention of ChREBP-dependent hepatic steatosis in mice. J Clin Invest. 2010;120(12):4316–31.PubMedPubMedCentralCrossRef
150.
Ceseña TI, Cui TX, Subramanian L, Fulton CT, Iñiguez-Lluhí JA, Kwok RP, et al. Acetylation and deacetylation regulate CCAAT/enhancer binding protein beta at K39 in mediating gene transcription. Mol Cell Endocrinol. 2008;289(1–2):94–101.PubMedCrossRef
151.
Watanabe H, Inaba Y, Kimura K, Matsumoto M, Kaneko S, Kasuga M, et al. Sirt2 facilitates hepatic glucose uptake by deacetylating glucokinase regulatory protein. Nat Commun. 2018;9(1):30.PubMedPubMedCentralCrossRef
152.
Dominy JE Jr, Lee Y, Jedrychowski MP, Chim H, Jurczak MJ, Camporez JP, et al. The deacetylase Sirt6 activates the acetyltransferase GCN5 and suppresses hepatic gluconeogenesis. Mol Cell. 2012;48(6):900–13.PubMedPubMedCentralCrossRef
153.
Lee Y, Dominy JE, Choi YJ, Jurczak M, Tolliday N, Camporez JP, et al. Cyclin D1-Cdk4 controls glucose metabolism independently of cell cycle progression. Nature. 2014;510(7506):547–51.PubMedPubMedCentralCrossRef
154.
Zhang C, Zhong T, Li Y, Li X, Yuan X, Liu L, et al. The hepatic AMPK-TET1-SIRT1 axis regulates glucose homeostasis. Elife. 2021;10.
155.
Sharabi K, Lin H, Tavares CDJ, Dominy JE, Camporez JP, Perry RJ, et al. Selective Chemical Inhibition of PGC-1α Gluconeogenic Activity Ameliorates Type 2 Diabetes. Cell. 2017;169(1):148-160.e115.PubMedPubMedCentralCrossRef
156.
Sharma S, Taliyan R. Histone deacetylase inhibitors: Future therapeutics for insulin resistance and type 2 diabetes. Pharmacol Res. 2016;113(Pt A):320–6.PubMedCrossRef
157.
Katafuchi T, Holland WL, Kollipara RK, Kittler R, Mangelsdorf DJ, Kliewer SA. PPARγ-K107 SUMOylation regulates insulin sensitivity but not adiposity in mice. Proc Natl Acad Sci U S A. 2018;115(48):12102–11.PubMedPubMedCentralCrossRef
158.
Chen Y, Zhao X, Wu H. Metabolic Stress and Cardiovascular Disease in Diabetes Mellitus: The Role of Protein O-GlcNAc Modification. Arterioscler Thromb Vasc Biol. 2019;39(10):1911–24.PubMedPubMedCentralCrossRef
159.
Gurel Z, Sheibani N. O-Linked β-N-acetylglucosamine (O-GlcNAc) modification: a new pathway to decode pathogenesis of diabetic retinopathy. Clin Sci (Lond). 2018;132(2):185–98.CrossRef
160.
Pontrelli P, Oranger A, Barozzino M, Conserva F, Papale M, Gesualdo L. The pathological role of the ubiquitination pathway in diabetic nephropathy. Minerva Med. 2018;109(1):53–67.PubMed
161.
Marré ML, Piganelli JD. Environmental Factors Contribute to β Cell Endoplasmic Reticulum Stress and Neo-Antigen Formation in Type 1 Diabetes. Front Endocrinol (Lausanne). 2017;8:262.CrossRef
162.
Strollo R, Vinci C, Napoli N, Pozzilli P, Ludvigsson J, Nissim A. Antibodies to post-translationally modified insulin as a novel biomarker for prediction of type 1 diabetes in children. Diabetologia. 2017;60(8):1467–74.PubMedPubMedCentralCrossRef
163.
Springhorn C, Matsha TE, Erasmus RT, Essop MF. Exploring leukocyte O-GlcNAcylation as a novel diagnostic tool for the earlier detection of type 2 diabetes mellitus. J Clin Endocrinol Metab. 2012;97(12):4640–9.PubMedCrossRef
164.
Lieberman SM, Evans AM, Han B, Takaki T, Vinnitskaya Y, Caldwell JA, et al. Identification of the beta cell antigen targeted by a prevalent population of pathogenic CD8+ T cells in autoimmune diabetes. Proc Natl Acad Sci U S A. 2003;100(14):8384–8.PubMedPubMedCentralCrossRef
165.
Mukherjee R, Wagar D, Stephens TA, Lee-Chan E, Singh B. Identification of CD4+ T cell-specific epitopes of islet-specific glucose-6-phosphatase catalytic subunit-related protein: a novel beta cell autoantigen in type 1 diabetes. J Immunol. 2005;174(9):5306–15.PubMedCrossRef
166.
Yang J, Danke NA, Berger D, Reichstetter S, Reijonen H, Greenbaum C, et al. Islet-specific glucose-6-phosphatase catalytic subunit-related protein-reactive CD4+ T cells in human subjects. J Immunol. 2006;176(5):2781–9.PubMedCrossRef
167.
Strollo R, Rizzo P, Spoletini M, Landy R, Hughes C, Ponchel F, et al. HLA-dependent autoantibodies against post-translationally modified collagen type II in type 1 diabetes mellitus. Diabetologia. 2013;56(3):563–72.PubMedCrossRef
168.
Scotto M, Afonso G, Larger E, Raverdy C, Lemonnier FA, Carel JC, et al. Zinc transporter (ZnT)8(186–194) is an immunodominant CD8+ T cell epitope in HLA-A2+ type 1 diabetic patients. Diabetologia. 2012;55(7):2026–31.PubMedPubMedCentralCrossRef
169.
Dang M, Rockell J, Wagner R, Wenzlau JM, Yu L, Hutton JC, et al. Human type 1 diabetes is associated with T cell autoimmunity to zinc transporter 8. J Immunol. 2011;186(10):6056–63.PubMedCrossRef
170.
Lockridge A, Jo S, Gustafson E, Damberg N, Mohan R, Olson M, et al. Islet O-GlcNAcylation Is Required for Lipid Potentiation of Insulin Secretion through SERCA2. Cell Rep. 2020;31(5): 107609.PubMedPubMedCentralCrossRef
171.
Jo S, Lockridge A, Alejandro EU. eIF4G1 and carboxypeptidase E axis dysregulation in O-GlcNAc transferase-deficient pancreatic β-cells contributes to hyperproinsulinemia in mice. J Biol Chem. 2019;294(35):13040–50.PubMedPubMedCentralCrossRef
172.
Chattopadhyay T, Maniyadath B, Bagul HP, Chakraborty A, Shukla N, Budnar S, et al. Spatiotemporal gating of SIRT1 functions by O-GlcNAcylation is essential for liver metabolic switching and prevents hyperglycemia. Proc Natl Acad Sci U S A. 2020;117(12):6890–900.PubMedPubMedCentralCrossRef
173.
Oliveri LM, Buzaleh AM, Gerez EN. An increase in O-GlcNAcylation of Sp1 down-regulates the gene expression of pi class glutathione S-transferase in diabetic mice. Biochem Biophys Rep. 2021;27: 101049.PubMedPubMedCentral
174.
Gonzalez-Rellan MJ, Fondevila MF, Fernandez U, Rodríguez A, Varela-Rey M, Veyrat-Durebex C, et al. O-GlcNAcylated p53 in the liver modulates hepatic glucose production. Nat Commun. 2021;12(1):5068.PubMedPubMedCentralCrossRef
175.
Berthier A, Vinod M, Porez G, Steenackers A, Alexandre J, Yamakawa N, et al. Combinatorial regulation of hepatic cytoplasmic signaling and nuclear transcriptional events by the OGT/REV-ERBα complex. Proc Natl Acad Sci U S A. 2018;115(47):E11033-e11042.PubMedPubMedCentralCrossRef
176.
Gaborit B, Govers R, Altié A, Brunel JM, Morange P, Peiretti F. The aminosterol Claramine inhibits β-secretase 1-mediated insulin receptor cleavage. J Biol Chem. 2021;297(1): 100818.PubMedPubMedCentralCrossRef
177.
Zhang X, Qiao Y, Wu Q, Chen Y, Zou S, Liu X, et al. The essential role of YAP O-GlcNAcylation in high-glucose-stimulated liver tumorigenesis. Nat Commun. 2017;8:15280.PubMedPubMedCentralCrossRef
178.
Ruan HB, Han X, Li MD, Singh JP, Qian K, Azarhoush S, et al. O-GlcNAc transferase/host cell factor C1 complex regulates gluconeogenesis by modulating PGC-1α stability. Cell Metab. 2012;16(2):226–37.PubMedPubMedCentralCrossRef
179.
Guinez C, Filhoulaud G, Rayah-Benhamed F, Marmier S, Dubuquoy C, Dentin R, et al. O-GlcNAcylation increases ChREBP protein content and transcriptional activity in the liver. Diabetes. 2011;60(5):1399–413.PubMedPubMedCentralCrossRef
180.
Housley MP, Rodgers JT, Udeshi ND, Kelly TJ, Shabanowitz J, Hunt DF, et al. O-GlcNAc regulates FoxO activation in response to glucose. J Biol Chem. 2008;283(24):16283–92.PubMedPubMedCentralCrossRef
181.
Anthonisen EH, Berven L, Holm S, Nygård M, Nebb HI, Grønning-Wang LM. Nuclear receptor liver X receptor is O-GlcNAc-modified in response to glucose. J Biol Chem. 2010;285(3):1607–15.PubMedCrossRef
182.
Yang Y, Fu M, Li MD, Zhang K, Zhang B, Wang S, et al. O-GlcNAc transferase inhibits visceral fat lipolysis and promotes diet-induced obesity. Nat Commun. 2020;11(1):181.PubMedPubMedCentralCrossRef
183.
Yang Y, Li X, Luan HH, Zhang B, Zhang K, Nam JH, et al. OGT suppresses S6K1-mediated macrophage inflammation and metabolic disturbance. Proc Natl Acad Sci U S A. 2020;117(28):16616–25.PubMedPubMedCentralCrossRef
184.
Parker GJ, Lund KC, Taylor RP, McClain DA. Insulin resistance of glycogen synthase mediated by o-linked N-acetylglucosamine. J Biol Chem. 2003;278(12):10022–7.PubMedCrossRef
185.
Qin X, Li X, Liu C, Chen Z. A novel mechanism of pre-transplant insulin resistance contributing to post-transplant complications: Cyclosporin A-induced O-GlcNAcylation. Biochem Biophys Res Commun. 2017;492(2):172–7.PubMedCrossRef
186.
Weyrauch LA, McMillin SL, Witczak CA. Insulin resistance does not impair mechanical overload-stimulated glucose uptake, but does alter the metabolic fate of glucose in mouse muscle. Int J Mol Sci. 2020;21(13).
187.
Shi H, Munk A, Nielsen TS, Daughtry MR, Larsson L, Li S, et al. Skeletal muscle O-GlcNAc transferase is important for muscle energy homeostasis and whole-body insulin sensitivity. Mol Metab. 2018;11:160–77.PubMedPubMedCentralCrossRef
188.
Wang X, Feng Z, Wang X, Yang L, Han S, Cao K, et al. O-GlcNAcase deficiency suppresses skeletal myogenesis and insulin sensitivity in mice through the modulation of mitochondrial homeostasis. Diabetologia. 2016;59(6):1287–96.PubMedCrossRef
189.
Moore M, Avula N, Jo S, Beetch M, Alejandro EU. Disruption of O-Linked N-Acetylglucosamine Signaling in Placenta Induces Insulin Sensitivity in Female Offspring. Int J Mol Sci. 2021;22(13).
Metadata
Title
Posttranslational modifications in diabetes: Mechanisms and functions
Authors
Ang Hu
Haohong Zou
Bin Chen
Jianing Zhong
Publication date
13-06-2022
Publisher
Springer US
Published in
Reviews in Endocrine and Metabolic Disorders / Issue 5/2022
Print ISSN: 1389-9155
Electronic ISSN: 1573-2606
DOI
https://doi.org/10.1007/s11154-022-09740-x

Other articles of this Issue 5/2022

Reviews in Endocrine and Metabolic Disorders 5/2022 Go to the issue

ReviewPaper

Diagnostic accuracy of bilateral inferior petrosal sinus sampling using desmopressin or corticotropic- releasing hormone in ACTH-dependent Cushing’s syndrome: A systematic review and meta-analysis

Correction

Correction to: The role of transforming growth factor beta in thyroid autoimmunity: current knowledge and future perspectives

ReviewPaper

Efficacy of radiofrequency and laser thermal ablation in solving thyroid nodule-related symptoms and cosmetic concerns. A systematic review and meta-analysis

ReviewPaper

Endocrinological and inflammatory markers in individuals with spinal cord injury: A systematic review and meta-analysis

ReviewPaper

Interactions between nuclear receptors glucocorticoid receptor α and peroxisome proliferator–activated receptor α form a negative feedback loop

ReviewPaper

Impulse control disorders in hyperprolactinemic patients on dopamine agonist therapy
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits